Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Queensland Health
Cantor Fitzgerald
Argus Health

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,501,409

« Back to Dashboard

Which drugs does patent 7,501,409 protect, and when does it expire?

Patent 7,501,409 protects STENDRA and is included in one NDA. There has been one Paragraph IV challenge on Stendra.

This patent has fourteen patent family members in eleven countries.

Summary for Patent: 7,501,409

Title:Preparations for oral administration
Abstract: The present invention provides a preparation for oral administration containing a medicinal substance having cGMP-specific phosphodiesterase inhibitory activity and showing decrease of solubility in the neutral and alkaline regions, wherein an acidic substance is compounded promote the dissolution of the medicinal substance in digestive tract and thus the efficacy can be expressed at the early stage after administration, and which preparation is useful in treatment of erectile dysfunction.
Inventor(s): Murakami; Hideki (Kobe, JP), Takebe; Shoji (Takatsuki, JP)
Assignee: Mitsubishi Tanabe Pharma Corporation (Osaka-shi, JP)
Application Number:10/363,322
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Metuchen Pharms
TABLET;ORAL202276-001Apr 27, 2012RXYesNo► Subscribe► SubscribeY
Metuchen Pharms
TABLET;ORAL202276-002Apr 27, 2012RXYesNo► Subscribe► SubscribeY
Metuchen Pharms
TABLET;ORAL202276-003Apr 27, 2012RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,501,409

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-270061Sep 06, 2000
Japan2001-231682Jul 31, 2001
PCT Information
PCT FiledSeptember 06, 2001PCT Application Number:PCT/JP01/07718
PCT Publication Date:March 14, 2002PCT Publication Number: WO02/20058

International Patent Family for Patent: 7,501,409

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2420461► Subscribe
China1264574► Subscribe
China1462193► Subscribe
European Patent Office1316316► Subscribe
Spain2381862► Subscribe
Japan4588973► Subscribe
South Korea20030029921► Subscribe
MexicoPA03001958► Subscribe
South Korea100610131► Subscribe
Austria552013► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
US Army
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus